2016-08-31

RetroSense Therapeutics Receives Patent on Proprietary Method for Restoring Vision using Optogenetics

RetroSense Therapeutics, a privately-held, clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent Application No. 11/036,629, entitled “Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration.” RetroSense is the exclusive licensee of this intellectual property for augmenting vision from photoreceptor cell degeneration through a license with Massachusetts General Hospital. This patent broadly covers methods for restoring or improving vision using optogenetic approaches. The allowed claims cover the use of a broad range of opsins and rhodopsins in vision restoration.
Continue reading

ViewSonic Corp., a leading global provider of visual and edtech solutions, announces the shipping of LDS138-151, a 138-inch all-in-one, mobile Direct View LED Display Solution Kit. The ViewSonic LDS138-151 is a fully pre-assembled kit that bui... READ MORE

With the rise of streaming services and endorsements from the Hollywood movie industry, an increasing number of movies, TV series, and documentary concert films are being produced using Virtual Production (VP) and Extended Reality (XR) technol... READ MORE